http://hl7.org/fhir/uv/ebm/Citation/179613
type: Citation
node role: treeRoot
id:
  v: 179613
meta:
  version id:
    v: 20
  last updated:
    v: 2025-10-13T12:34:35.118Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation
    l: journal-article-citation
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: Citation 179613 version: 20; Last updated: 2025-10-13 12:34:35+0000 Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: Citation 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. identifier: FEvIR Object Identifier/179613, https://pubmed.ncbi.nlm.nih.gov/27308831, <a href="http://terminology.hl7.org/7.0.1/NamingSystem-uri.html" title="As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt #xD;#xA;#xD;#xA;This oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: #xD;#xA;#xD;#xA;Note that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.#xD;#xA;#xD;#xA;This OID may also be used in CD.codeSystem.">Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.27 version: 1.0.0-ballot3 title: 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. status: Active date: 2026-01-08 11:24:31+0000 author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: HL7 International / Clinical Decision Support contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Gu…
contained: Practitioner
  id:
    v: contributor0
  name:
    family:
      v: Botrel
    given:
      v: Tobias Engel Ayer
contained: Practitioner
  id:
    v: contributor1
  name:
    family:
      v: Clark
    given:
      v: Otávio
contained: Practitioner
  id:
    v: contributor2
  name:
    family:
      v: Lima Pompeo
    given:
      v: Antônio Carlos
contained: Practitioner
  id:
    v: contributor3
  name:
    family:
      v: Horta Bretas
    given:
      v: Francisco Flávio
contained: Practitioner
  id:
    v: contributor4
  name:
    family:
      v: Sadi
    given:
      v: Marcus Vinicius
contained: Practitioner
  id:
    v: contributor5
  name:
    family:
      v: Ferreira
    given:
      v: Ubirajara
contained: Practitioner
  id:
    v: contributor6
  name:
    family:
      v: Borges Dos Reis
    given:
      v: Rodolfo
contained: ArtifactAssessment
  id:
    v: meshHeading0
  artifact: Reference
    l: #
    reference:
      v: #
    type:
      v: Citation
      l: Citation
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D000368
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D000726
    free to share:
      v: true
    component:
      classifier:
        coding: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D000970
    free to share:
      v: true
    component:
      classifier:
        coding: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D000971
    free to share:
      v: true
    component:
      classifier:
        coding: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: http://id.nlm.nih.gov/mesh/D000077143
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D006801
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D008207
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D008297
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D008875
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D061214
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D011471
    free to share:
      v: true
    component:
      classifier:
        coding: Q000188
    component:
      classifier:
        coding: Q000401
    component:
      classifier:
        coding: Q000473
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D016032
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings

v: mesh-heading

v: MeSH heading

v: D000368

v: Aged

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000726

v: Androgen Antagonists

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000627
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D000970

v: Antineoplastic Agents

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000627
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D000971

v: Antineoplastic Combined Chemotherapy Protocols

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000627
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D000077143

v: Docetaxel

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D006801

v: Humans

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D008207

v: Lymphatic Metastasis

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D008297

v: Male

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D008875

v: Middle Aged

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D061214

v: Patient Safety

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D011471

v: Prostatic Neoplasms

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000188
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000188
display:
  v: drug therapy

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: qualifier

Q000401
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000401
display:
  v: mortality

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: qualifier

Q000473
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000473
display:
  v: pathology

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: mesh-heading

v: MeSH heading

v: D016032

v: Randomized Controlled Trials as Topic

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

coding: D016019
  system:
    v: https://www.nlm.nih.gov/mesh
    l: mesh
  code:
    v: D016019
  display:
    v: Survival Analysis
  user selected:
    v: false

v: true

type:
  text:
    v: qualifier
classifier:
  text:
    v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D043823
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D043823
    display:
      v: Taxoids
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic
component:
  type:
    text:
      v: qualifier
  classifier:
    coding: Q000627
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000627
      display:
        v: therapeutic use
  component:
    type:
      text:
        v: is Major topic

v: C49488

v: Yes

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D016896
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016896
    display:
      v: Treatment Outcome
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D050257
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D050257
    display:
      v: Tubulin Modulators
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic
component:
  type:
    text:
      v: qualifier
  classifier:
    coding: Q000627
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000627
      display:
        v: therapeutic use
  component:
    type:
      text:
        v: is Major topic

v: C49488

v: Yes

url:
  v: http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status
  l: artifact-publication-status
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-status-type
      l: cited-artifact-status-type
    code:
      v: active
    display:
      v: Active

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v2-0203
      l: v2-0203
    code:
      v: ACSN
    display:
      v: Accession ID
  text:
    v: FEvIR Object Identifier
system:
  v: https://fevir.net/FOI
  l: FOI
value:
  v: 179613
assigner:
  display:
    v: Computable Publishing LLC

system:
  v: https://pubmed.ncbi.nlm.nih.gov
  l: pubmed.ncbi.nlm.nih.gov
value:
  v: 27308831

system:
  v: urn:ietf:rfc:3986
  l: 3986
value:
  v: urn:oid:2.16.840.1.113883.4.642.40.44.15.27

v: 1.0.0-ballot3

v: 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.

v: active

v: 2026-01-08T11:24:31+00:00

name:
  v: Computable Publishing®: MEDLINE-to-FEvIR Converter

v: HL7 International / Clinical Decision Support

name:
  v: HL7 International / Clinical Decision Support
telecom:
  system:
    v: url
  value:
    v: http://www.hl7.org/Special/committees/dss

v: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

code:
  system:
    v: http://terminology.hl7.org/CodeSystem/citation-classification-type
    l: citation-classification-type
  code:
    v: fevir-platform-use
  display:
    v: FEvIR Platform Use
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: medline-base
    display:
      v: Medline Base
    user selected:
      v: false

coding:
  system:
    v: http://unstats.un.org/unsd/methods/m49/m49.htm
    l: m49.htm
  code:
    v: 001
  display:
    v: World

v: 2017-07-26

v: 2024-03-27

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: citation-source
    display:
      v: Citation Source
classifier:
  text:
    v: MEDLINE

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: medline-owner
    display:
      v: MEDLINE Citation Owner
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value
      l: owner value
    code:
      v: NLM
    display:
      v: National Library of Medicine, Index Section
    user selected:
      v: false

coding:
  system:
    v: http://hl7.org/fhir/citation-status-type
    l: citation-status-type
  code:
    v: medline-medline
  display:
    v: Medline Citation Status of Medline

coding:
  system:
    v: http://hl7.org/fhir/citation-status-type
    l: citation-status-type
  code:
    v: pubmed-publication-status-epublish
  display:
    v: PubMed PublicationStatus of epublish

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-received
    display:
      v: PubMed Pubstatus of Received
period:
  end:
    v: 2016-04-01

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-accepted
    display:
      v: PubMed Pubstatus of Accepted
period:
  end:
    v: 2016-06-02

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-entrez
    display:
      v: PubMed Pubstatus of Entrez
period:
  end:
    v: 2016-06-17T06:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-pubmed
    display:
      v: PubMed Pubstatus of Pubmed
period:
  end:
    v: 2016-06-17T06:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-medline
    display:
      v: PubMed Pubstatus of Medline
period:
  end:
    v: 2017-07-27T06:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-pmc-release
    display:
      v: PubMed Pubstatus of PMC release
period:
  end:
    v: 2016-06-16

identifier:
  system:
    v: https://pubmed.ncbi.nlm.nih.gov
    l: pubmed.ncbi.nlm.nih.gov
  value:
    v: 27308831
identifier:
  system:
    v: https://www.ncbi.nlm.nih.gov/pmc/
    l: pmc
  value:
    v: PMC4911003
identifier:
  system:
    v: https://doi.org
    l: doi.org
  value:
    v: 10.1371/journal.pone.0157660
identifier:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/v2-0203
        l: v2-0203
      code:
        v: ACSN
      display:
        v: Accession ID
    text:
      v: pii
  value:
    v: PONE-D-16-10077
title:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/title-type
        l: title-type
      code:
        v: primary
      display:
        v: Primary title
  text:
    v: Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
abstract:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type
        l: cited-artifact-abstract-type
      code:
        v: primary-human-use
      display:
        v: Primary human use
  text:
    v: **OBJECTIVE:** Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in older men in the United States (USA) and Western Europe. Androgen-deprivation therapy alone (ADT) remains the first line of treatment in most cases, for metastatic disease. We performed a systematic review and meta-analysis of all randomized controlled trials (RCT) that compared the efficacy and adverse events profile of a chemohormonal therapy (ADT ± docetaxel) for metastatic hormone-naive prostate cancer (mHNPC). **METHODS:** Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoint was overall survival. Data extracted from the studies were combined by using the hazard ratio (HR) or risk ratio (RR) with their corresponding 95% confidence intervals (95% CI). **RESULTS:** The final analysis included 3 trials comprising 2,264 patients (mHNPC). Patients who received the chemohormonal therapy had a longer clinical progression-free survival interval (HR = 0.64; 95% CI: 0.55 to 0.75; p<0.00001), and no heterogeneity (Chi2 = 0.64; df = 1 [p = 0.42]; I2 = 0%). The biochemical progression-free survival (bPFS) also was higher in patients treated with ADT plus docetaxel (HR = 0.63; 95% CI: 0.57 to 0.69; p<0.00001), also with no heterogeneity noted (Chi2 = 0.48; df = 2 [p = 0.79]; I2 = 0%). Finally, the combination of ADT with docetaxel showed a superior overall survival (OS) compared with ADT alone (HR = 0.73; 95% CI: 0.64 to 0.84; p<0.0001), with moderate heterogeneity (Chi2 = 3.84; df = 2 [p = 0.15]; I2 = 48%). A random-effects model analysis was performed, and the results remained favorable to the use of ADT plus docetaxel (HR = 0.73; 95% CI: 0.60 to 0.89; p = 0.002). In the final combined analysis of the high-volume disease patients, the use of the combination therapy also favored an increased overall survival (HR = 0.67; 95% CI: 0.54 to 0.83; p = 0.0003). Regarding adverse events and severe toxicity (grade ≥3), t…
relates to:
  type:
    v: cites
  citation:
    v: http://clinicaltrials.gov/ct2/show/NCT00514540.
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011;60(2):279–90. Epub 2011/05/20. doi: S0302-2838(11)00477-5 [pii] 10.1016/j.eururo.2011.04.038 .
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, et al. Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis. International braz j urol: official journal of the Brazilian Society of Urology. 2012;38(6):717–27. Epub 2013/01/11. .
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25(12):1596–605. Epub 2007/04/04. doi: JCO.2006.10.1949 [pii] 10.1200/JCO.2006.10.1949 .
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. European urology. 2014;65(2):467–79. Epub 2013/12/11. 10.1016/j.eururo.2013.11.002 .
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v69–77. Epub 2015/07/25. 10.1093/annonc/mdv222 .
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Noguchi M, Noda S, Yoshida M, Ueda S, Shiraishi T, Itoh K. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol. 2004;11(2):103–9. Epub 2004/01/07. .
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England journal of medicine. 2004;351(15):1513–20. Epub 2004/10/08. 10.1056/NEJMoa041318 .
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England journal of medicine. 2004;351(15):1502–12. Epub 2004/10/08. 10.1056/NEJMoa040720 .
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Fizazi K, Jenkins C, Tannock IF. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol. 2015;26(8):1660–7. Epub 2015/05/24. 10.1093/annonc/mdv245
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2013;14(2):149–58. Epub 2013/01/12. 10.1016/s1470-2045(12)70560-0 .

type:
  v: cites
citation:
  v: Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy plus docetaxel versus ADT alone for hormone-naive metastatic prostate cancer: Long-term analysis of the GETUG-AFU 15 phase III trial. 2015 Genitourinary Cancers Symposium Abstract 140 Presented February 26, 2015.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F, et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. European urology. 2015. Epub 2015/11/28. 10.1016/j.eururo.2015.11.005 .

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015;373(8):737–46. Epub 2015/08/06. 10.1056/NEJMoa1503747

type:
  v: cites
citation:
  v: Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 32:5s, 2014. (suppl; abstr LBA2).

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309(6964):1286–91. Epub 1994/11/12. .

type:
  v: cites
citation:
  v: Clarke M, Oxman AD, (Editors). Cochrane Reviewers Handbook 4.1.1 [updated December 2000] In: The Cochrane Library, Issue 4, 2000. Oxford, Update Software.2000.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Castro AA, Clark OA, Atallah AN. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. Sao Paulo Med J. 1999;117(3):138–9. Epub 1999/10/08. doi: S1516-3180(99)11700311 [pii]. .

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Egger M, Smith GD, Altman D. Systematic Reviews in Health Care. London: BMJ Books; 2001.

type:
  v: cites
citation:
  v: Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34. Epub 1999/01/28. [pii]. .

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. Epub 2003/09/06. 10.1136/bmj.327.7414.557 327/7414/557 [pii].

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig. 2010;30(4):229–41. Epub 2010/03/17. doi: 2 [pii] 10.2165/11532260-000000000-00000 .

type:
  v: cites
citation:
  v: Deeks JJ, Higgins JP, Altman DG. Analysing and presenting results In: Higgins JP, G S editor. Cochrane Handbook for Systematic Reviews of In- terventions (ed 426 [updated September 2006]). Chichester, United Kingdom: John Wiley & Sons Ltd; 2006.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. Epub 1986/09/01. doi: 0197-2456(86)90046-2 [pii]. .

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. Epub 1997/10/06.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126(9):712–20. Epub 1997/05/01. .

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses—sometimes informative, usually misleading. BMJ. 1999;318(7197):1548–51. Epub 1999/06/04.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol. 2002;2:3 Epub 2002/02/28.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–94. Epub 2009/07/23. doi: 0000605-200908180-00136 [pii].

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. The Lancet Oncology. 2015;16(7):787–94. Epub 2015/06/02. 10.1016/s1470-2045(15)00011-x .

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, et al. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology. 2013;81(3):611–6. Epub 2013/03/05. 10.1016/j.urology.2012.12.025 .

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Thalgott M, Horn T, Heck MM, Maurer T, Eiber M, Retz M, et al. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. Journal of hematology & oncology. 2014;7:20 Epub 2014/03/07. 10.1186/1756-8722-7-20

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. European urology. 2012;62(2):213–9. Epub 2012/04/17. 10.1016/j.eururo.2012.03.053 .

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (London, England). 2011;378(9809):2104–11. Epub 2011/11/08. 10.1016/s0140-6736(11)61095-7

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (London, England). 2009;373(9660):301–8. Epub 2008/12/19. 10.1016/s0140-6736(08)61815-2 .

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Amato R, Stepankiw M, Gonzales P. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. Cancer chemotherapy and pharmacology. 2013;71(6):1629–34. Epub 2013/04/23. 10.1007/s00280-013-2163-4 .

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Rajan P, Frew JA, Wilson JM, Azzabi AS, McMenemin RM, Stockley J, et al. Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer. Urol Oncol. 2015;33(8):337.e1–6. Epub 2015/06/21. 10.1016/j.urolonc.2015.05.012 .

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European urology. 2015;67(6):1028–38. Epub 2014/10/11. 10.1016/j.eururo.2014.09.032 .

type:
  v: cites
citation:
  v: James ND, Sydes MR, Mason M, et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 33, 2015. (suppl; abstr 5001).

type:
  v: cites
citation:
  v: Patrick-Miller LJ, Chen YH, Carducci MA, Cella D, DiPaola RS, Gartrell BA, et al. Quality of life (QOL) analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PrCa). J Clin Oncol 34, 2016. (suppl 2S; abstr 286).

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Morgan SC, Waldron TS, Eapen L, Mayhew LA, Winquist E, Lukka H. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol. 2008;88(1):1–9. Epub 2008/05/27. doi: S0167-8140(08)00233-8 [pii] 10.1016/j.radonc.2008.04.013 .

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26(8):1589–604. Epub 2015/06/05. 10.1093/annonc/mdv257

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. The Lancet Oncology. 2013;14(2):117–24. Epub 2013/01/09. 10.1016/s1470-2045(12)70537-5 .

type:
  v: cites
citation:
  v: Kellokumpu-Lehtinen PL, Harmenberg U, Hervonen P, Joensuu TK, McDermott RS, Ginman C, et al. Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis. J Clin Oncol 32, 2014. (suppl 4; abstr 23).

type:
  v: cites
citation:
  v: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer (Version 1.2016). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

type:
  v: cites
citation:
  v: Liaw BC, Oh WK. Is Docetaxel Chemotherapy a New Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer? The American Journal of Hematology/oncology 2015; 11(9):17–20

published in:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/published-in-type
        l: published-in-type
      code:
        v: D020492
      display:
        v: Periodical
  identifier:
    type:
      text:
        v: Electronic ISSN Type
    system:
      v: https://portal.issn.org
      l: portal.issn.org
    value:
      v: 1932-6203
  identifier:
    type:
      text:
        v: ISOAbbreviation
    system:
      v: https://www.issn.org/services/online-services/access-to-the-ltwa/
      l: access-to-the-ltwa
    value:
      v: PLoS One
  identifier:
    type:
      text:
        v: ISSN Linking
    system:
      v: https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/
      l: the-issn-l-for-publications-on-multiple-media
    value:
      v: 1932-6203
  identifier:
    type:
      text:
        v: Medline Title Abbreviation
    system:
      v: https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html
      l: contructitleabbre.html
    value:
      v: PLoS One
  identifier:
    type:
      text:
        v: NLM Unique ID
    system:
      v: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
      l: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
    value:
      v: 101285081
  title:
    v: PloS one
  publisher location:
    v: United States
cited medium:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-medium
      l: cited-medium
    code:
      v: internet
    display:
      v: Internet
volume:
  v: 11
issue:
  v: 6
article date:
  v: 2016
page string:
  v: e0157660

v: Electronic

v: Electronic

v: XX

v: Organization identifier

v: XX

v: Organization identifier

v: XX

v: Organization identifier

v: XX

v: Organization identifier

cited medium:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-medium
      l: cited-medium
    code:
      v: internet-without-issue
    display:
      v: Internet without issue
article date:
  v: 2016-06-16

classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: abstract
    display:
      v: Abstract
url:
  v: https://pubmed.ncbi.nlm.nih.gov/27308831/
  l: https://pubmed.ncbi.nlm.nih.gov/27308831/

classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: doi-based
    display:
      v: DOI Based
url:
  v: https://doi.org/10.1371/journal.pone.0157660
  l: journal.pone.0157660

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publishing-model
    display:
      v: Publishing Model
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: Electronic-eCollection
    display:
      v: Electronic-eCollection
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: chemical
    display:
      v: Chemical
    user selected:
      v: false
classifier:
  coding: D000726
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000726
    display:
      v: Androgen Antagonists
    user selected:
      v: false
classifier:
  coding: D000970
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000970
    display:
      v: Antineoplastic Agents
    user selected:
      v: false
classifier:
  coding: D043823
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D043823
    display:
      v: Taxoids
    user selected:
      v: false
classifier:
  coding: D050257
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D050257
    display:
      v: Tubulin Modulators
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.cas.org/support/documentation/chemical-substances
      l: chemical-substances
    code:
      v: 15H5577CQD
    user selected:
      v: false
  coding: http://id.nlm.nih.gov/mesh/D000077143
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000077143
    display:
      v: Docetaxel
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
artifact assessment:
  l: meshHeading0
  reference:
    v: #meshHeading0
  type:
    v: ArtifactAssessment
    l: ArtifactAssessment

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publication-type
    display:
      v: Publication type
classifier:
  coding: D016428
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
classifier:
  coding: D017418
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D017418
    display:
      v: Meta-Analysis
    user selected:
      v: false
classifier:
  coding: D016454
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016454
    display:
      v: Review
    user selected:
      v: false
classifier:
  coding: http://id.nlm.nih.gov/mesh/D000078182
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000078182
    display:
      v: Systematic Review
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: knowledge-artifact-type
    display:
      v: Knowledge Artifact Type
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
artifact assessment:
  display:
    v: Classifier added by Computable Publishing LLC

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: citation-subset
    display:
      v: Citation subset
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset
      l: citationsubset
    code:
      v: IM
    display:
      v: IM
    user selected:
      v: false

complete:
  v: true
entry:
  contributor:
    l: contributor0
    reference:
      v: #contributor0
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Botrel TE
  forename initials:
    v: TE
  affiliation:
    display:
      v: Evidencias - A Kantar Health Company, Campinas, São Paulo, Brazil.
  affiliation:
    display:
      v: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.
entry:
  contributor:
    l: contributor1
    reference:
      v: #contributor1
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Clark O
  forename initials:
    v: O
  affiliation:
    display:
      v: Evidencias - A Kantar Health Company, Campinas, São Paulo, Brazil.
  affiliation:
    display:
      v: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.
entry:
  contributor:
    l: contributor2
    reference:
      v: #contributor2
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Lima Pompeo AC
  forename initials:
    v: AC
  affiliation:
    display:
      v: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.
entry:
  contributor:
    l: contributor3
    reference:
      v: #contributor3
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Horta Bretas FF
  forename initials:
    v: FF
  affiliation:
    display:
      v: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.
entry:
  contributor:
    l: contributor4
    reference:
      v: #contributor4
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Sadi MV
  forename initials:
    v: MV
  affiliation:
    display:
      v: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.
entry:
  contributor:
    l: contributor5
    reference:
      v: #contributor5
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Ferreira U
  forename initials:
    v: U
  affiliation:
    display:
      v: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.
entry:
  contributor:
    l: contributor6
    reference:
      v: #contributor6
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Borges Dos Reis R
  forename initials:
    v: R
  affiliation:
    display:
      v: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.